- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
March 2024e-Commerce: Pitfalls and Protections
-
March 22, 2024‘In re Cellect’:
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Generic Launches
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
April 16, 2013
Reference Listed Drug | NDA Holder | Generic Drug Name | ANDA Applicant(s) | Indication | Launch Date |
Propecia | Merck Sharp & Dohme | Finasteride | Dr. Reddy's Labs | male pattern hair loss | 1/2/2013 |
Maxalt | Merk | Rizatriptan Benzoate Tablets | Glenmark Generics | migraine with or without aura in adults | 1/2/2013 |
Maxalt MLT and Maxalt | Merck | Rizatriptan Benzoate Orally Disintegrating, Rizatriptan Benzoate Tablets |
Mylan Phamaceuticals | migraine with or without aura in adults | 1/2/2013 |
Maxalt MLT and Maxalt | Merk | Rizatriptan benzoate | Par Pharmaceutical | migraine with or without aura in adults | 1/2/2013 |
Romazicon | Hoffmann La Roche | Flumazenil Injection, USP | Sagent Pharmaceuticals | reversal of the sedative effects of benzodiazepines. | 1/2/2013 |
Lysteda | Ferring | Tranexamic Acid | Prasco | cyclic heavy menstrual bleeding | 1/7/2013 |
Acetadote | Cumberland Pharmaceuticals | Acetylcysteine injection | Perrigo | hepatic injury | 1/7/2013 |
Lamictal XR | GlaxoSmithKline | Lamotrigine | Wockhardt | epilepsy | 1/8/2013 |
Duetact | Takeda Pharmaceuticals | Pioglitazone Hydrochloride and Glimepiride tablets | Sandoz | control of blood sugar in adults with type 2 diabetes mellitus. | 1/11/2013 |
Luxiq Foam | Cobrek Pharmaceuticals | Betamethasone valerate foam 0.12% | Perrigo | scalp psoriasis | 1/15/2013 |
Lamictal XR | GlaxoSmithKline | Lamotrigine ER | Par Pharmaceutical | adjunctive therapy for partial onset seizures | 1/18/2013 |
Nicorette Mini | GlaxoSmithKline | Nicotine polacrilex mini lozenge USP | Perrigo | reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking | 1/22/2013 |
Bactroban | GlaxoSmithKline | Mupirocin | Glenmark Generics | secondarily infected traumatic skin lesions | 1/24/2013 |
Bactroban | GlaxoSmithKline | Mupirocin (authorized generic) | Prasco | secondarily infected traumatic skin lesions | 1/24/2013 |
Olux-E | GlaxoSmithKline | Clobetasol Emulsion Propionate foam, 0.05% | Perrigo | moderate to severe dermatosis of the scalp | 2/1/2013 |
Doxil | Janssen | Doxorubicin HCl | Sun Pharma | ovarian cancer that progressed or recurred after platinum-based chemotherapy. AIDS related Kaposi's sarcoma; combination with Velcade for multiple myeloma |
2/4/2013 |
Cleocin Phosphate® | Pharmacia and Upjohn | Clindamycin in 5% Dextrose in minibag form | Sandoz | serious bacterial infections | 2/6/2013 |
Argatroban | Eagle Pharmaceutical | Argatroban injection 50 mg/50mL, aqueous solution (1 mg/mL) | Sandoz | thrombosis in adult patients with heparin-induced thrombocytopenia. | 2/19/2013 |
Suboxone | Rickitt Benckiser Healthcare | Buprenorphine HCl and Naloxone HCl Dihydrate SL | Actavis | pain: Maintenance treatment of opioid dependence | 2/25/2013 |
Antara | Lupin Atlantis Holdings | Fenofibrate Capsules USP | Mylan Pharmaceuticals | reduce elevated LDL-C, Total-C, triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia and to reduce triglyceride levels in adult patients with severe hyper-triglyceridemia | 2/25/2013 |
Malarone | GlaxoSmithKline | Atovaquone Proguanil | Glenmark Generics | prophylaxis and treatment of acute, uncomplicated plasmodium falciparum malaria | 2/28/2013 |
Zometa | Novartis | Zoledronic Acid Injection | Dr. Reddy's Labs | hypercalcemia of malignancy | 3/5/2013 |
Zometa | Novartis | Zoledronic Acid | Sagent Pharmaceuticals | hypercalcemia of malignancy, patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy | 3/5/2013 |
Luvox CR | Jazz Pharmaceuticals | Fluvoxamine Maleate | Par Pharmaceutical | obsessive compulsive disorder | 3/14/2013 |
Xopenex | Sunovion | Levalbuterol Inhalation Solution | Mylan Specialty | bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease | 3/18/2013 |
Mucinex® | Reckitt Benckiser LLC | Guaifenesin Extended-Release | Perrigo | to relieve chest congestion and make coughs more productive | 3/18/2013 |
Ortho Cyclen and Ortho Tri-Cyclen | Janssen | Norgestimate and Ethinyl Estradiol Tablets | Sandoz | oral contraceptives; treatment of moderate acne in women at least 15 yrs. of age who additionally desire an oral contraceptive for birth control | 3/19/2013 |
Diovan HCT | Novartis | Valsartan and hydrochlorothiazide tablets | Lupin Pharmaceuticals | hypertension | 3/22/2013 |
Accutane | Hoffman-LaRoche | Isotretinoin Capsules USP | Dr. Reddy's Labs | severe nodular acne | 3/28/2013 |
GENERICally Speaking Spring 2013
Related Publications
Fourth Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
December 29, 2023
Corcept Therapeutics, Inc. v. Teva Pharms. USA, Inc.
GENERICally Speaking Hatch Waxman Bulletin
December 13, 2023
Acadia Pharms. Inc. v. Aurobindo Pharma Ltd.
GENERICally Speaking Hatch Waxman Bulletin
December 7, 2023
H. Lundbeck A/S v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
November 7, 2023
Eisai R&D Mgmt. Co., Ltd. v. Dr Reddy’s Labs., Inc.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.